Source:http://linkedlifedata.com/resource/pubmed/id/20919860
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
10
|
| pubmed:dateCreated |
2010-10-5
|
| pubmed:abstractText |
An increasing incidence of Pneumocystis jiroveci pneumonia (PCP) in patients with B-cell non-Hodgkin lymphoma (B-NHL) receiving rituximab treatment has been reported. We reviewed patients with B-NHL who underwent chemotherapy from 2004 to 2008 at our institution to identify risk factors for PCP development during and after chemotherapy. Among 297 patients with B-NHL, six developed PCP. Of 121 patients (41%) who received PCP prophylaxis with sulfamethoxazole–trimethoprim during chemotherapy, none developed PCP (0%), while among 176 patients (59%) who had no prophylaxis, six (3.4%) developed PCP at a median of 2 months (range: 1–3 months) after starting chemotherapy. Patients with CD4+ lymphocyte counts ?200/mm3 before chemotherapy had a higher risk of developing PCP (p=0.045), while a history of rituximab treatment was not related to PCP. CD4+ lymphocyte counts ?200/mm3 during and after chemotherapy were observed in 18.9% of patients.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Oct
|
| pubmed:issn |
1029-2403
|
| pubmed:author | |
| pubmed:issnType |
Electronic
|
| pubmed:volume |
51
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1816-21
|
| pubmed:meshHeading |
pubmed-meshheading:20919860-Adult,
pubmed-meshheading:20919860-Aged,
pubmed-meshheading:20919860-Aged, 80 and over,
pubmed-meshheading:20919860-Analysis of Variance,
pubmed-meshheading:20919860-Antibodies, Monoclonal, Murine-Derived,
pubmed-meshheading:20919860-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:20919860-CD4 Lymphocyte Count,
pubmed-meshheading:20919860-CD4-CD8 Ratio,
pubmed-meshheading:20919860-Drug Therapy, Combination,
pubmed-meshheading:20919860-Female,
pubmed-meshheading:20919860-Humans,
pubmed-meshheading:20919860-Lymphoma, B-Cell,
pubmed-meshheading:20919860-Male,
pubmed-meshheading:20919860-Middle Aged,
pubmed-meshheading:20919860-Pneumocystis jirovecii,
pubmed-meshheading:20919860-Pneumonia, Pneumocystis,
pubmed-meshheading:20919860-Risk Assessment,
pubmed-meshheading:20919860-Risk Factors,
pubmed-meshheading:20919860-Treatment Outcome,
pubmed-meshheading:20919860-Trimethoprim-Sulfamethoxazole Combination,
pubmed-meshheading:20919860-Young Adult
|
| pubmed:year |
2010
|
| pubmed:articleTitle |
Pneumocystis jiroveci pneumonia in relation to CD4+ lymphocyte count in patients with B-cell non-Hodgkin lymphoma treated with chemotherapy.
|
| pubmed:affiliation |
Hematology Division, National Cancer Center Hospital, Tokyo, Japan.
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|